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Abstract 
Objectives: The purpose of this retrospective study was to assess the impact of 
microbiological diagnostics on the outcomes of periodontal treatment with or without 
adjunctive use of systemic antibiotics. 
Materials and methods: Patient files were screened for microbiological analysis before (T1) 
and after non-surgical periodontal therapy (T2). Medical history, diagnosis, clinical data and 
results of the microbiological analysis were extracted from the patient’s file. After descriptive 
statistics logistic regression analysis was performed to model the presence of 90% and 50% 
reductions of numbers of sites with probing depths (PD) of ≥5 mm at T2 (90%-PD5 and 50%-
PD5), respectively against the presence of bacterial species, clinical diagnosis, and 
adjunctive use of systemic antibiotics. 
Results: Eighteen patients diagnosed with aggressive periodontitis (AP, 17 with adjunctive 
antibiotics) and 84 with chronic periodontitis (CP, 31 with adjunctive antibiotics) were 
included in the analysis. Logistic modeling of bacteria at T1 to 90%-PD5 failed to show any 
statistical significance. Using 50%-PD5, presence of all Porphyromonas gingivalis, 
Tannerella forsythia and Treponema denticola and in particular of T. denticola at T1 was 
associated with good response to therapy. Modeling of bacterial presence to 90-%PD5 and 
to 50-%PD5 at T2 found an association with absence of T. forsythia (90-%PD5 and 50-
%PD5) and of T. denticola and Campylobacter rectus (50%-PD5). Modeling bacteria at T1, 
antibiotic group and oral hygiene at T2 on 50%-PD5 revealed odds ratio (OR) of the 
adjunctive antibiotic group between 2.70 and 52.4, of the oral hygiene between 3.27 and 
4.11, and of the bacteria at T1 up to 28.6 (Porphyromonas gingivalis, T. forsythia, or T. 
denticola). 
Conclusion: Microbiological analysis of the most important species associated with 
periodontal diseases appears to support a clinically-based decision for the adjunctive use of 
systemic antibiotics. 
Clinical relevance: The present findings appear to support the use microbiological testing to 
strengthen the clinical decision making process for either using or not using systemic 
antibiotics in conjunction with non-surgical periodontal therapy. 
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Introduction 
Periodontitis is a chronic inflammatory disease of the tooth supporting tissues associated 
with high counts of certain bacterial species interacting with the host’ immune system [1]. 
Treatment protocols include removal of the biofilm from the affected teeth [2] with or without 
the adjunctive application of systemic antibiotics. Evidence from clinical studies indicates that 
the systemic use of amoxicillin combined with metronidazole significantly improves the 
outcomes of mechanical periodontal treatment [3, 4]. Irrespective of these results, a global 
problem is the development of resistance which is clearly associated with the consumption of 
antibiotics [5]. Nowadays, antimicrobial stewardships were implemented to prevent the rise of 
antimicrobial resistance, this includes fast identification of microbes and their resistance [6]. 
One of ten antibiotic prescriptions in human are made by dentists which might contribute to 
the critically important problem of bacterial resistance [7].   
In periodontitis, however, biofilm consist of several hundred species [8]. Standard 
microbiological diagnostics of periodontitis is a nucleic-acid based one determining a few 
selected species with no further antibiotic resistance profile. This includes Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, and Treponema 
denticola. A. actinomycetemcomitans has been associated in particular with localized 
aggressive periodontitis, leukotoxin, cytolethal distending toxin and lipopolysaccharide are 
well investigated virulence factors [9]. P. gingivalis, T. forsythia and T. denticola are 
members of the “red complex” according to the classification by Socransky, Haffajee and co-
workers [10]. They occur together as late colonizers in biofilm formation, and all of them have 
a high proteolytic activity [11]. Meanwhile P. gingivalis was postulated being a key-stone 
pathogen in changing a symbiotic microbiota into a dysbiotic one by modulating host 
response [12]. Other bacterial species like Prevotella intermedia, Parvimonas micra, 
Eikenella corrodens, Fusobacterium nucleatum, Campylobacter rectus are additionally 
analyzed in microbiological test kits available on the market [13, 14]. 
In a previous survey it was shown that most of the European oral microbiology laboratories 
do not participate in external and internal quality controls [15]. Culture and PCR techniques 
still have methodical problems when applied in oral microbiology [16]. Sampling of plaque 
may influence microbiological results [17]. In 2011, a statement was published that routine 
analysis of subgingival plaque is not necessarily benefitting the patient [18]. Moreover, 
adjunctive application of antibiotics resulted in excellent clinical results regardless whether 
the major periodontopathogens were tested both positive or negative [19]. 
At the Department of Periodontology, University of Bern, a method based on DNA-strip 
technology (micro-IDent®plus11 and microIDent®, Hain Lifescience, Nehren, Germany) has 
4 
 
been used for several years. This commercially available test is CE-labelled and has been 
evaluated several times [13, 20]. It is available as a five-species kit (A. 
actinomycetemcomitans, P. gingivalis, T. forsythia, T. denticola, P. intermedia) and an 11-
species kit (the five species plus P. micra, F. nucleatum/necrophorum, Campylobacter 
rectus, E. corrodens, Eubacterium nodatum, Capnocytophaga sp.). Samples for 
microbiological analyses are taken in a standardized manner (deepest site per quadrant) and 
at defined time points (before and after scaling and root planing). Additionally, the treatment 
protocol for periodontitis follows clearly defined guidelines. The use of systemic antibiotics is 
limited to the treatment of patients with Aggressive Periodontitis (AP) and severe forms of 
generalized Chronic Periodontitis (CP) defined as two sites with PD ≥7 mm per quadrant, 
and PI (O’Leary [21]) ≤0.25 
However, the issue on the impact of microbiological diagnosis on the decision making 
process for the use or not of systemic antibiotics in conjunction with subgingival mechanical 
debridement is still controversially discussed in the literature. 
Therefore, the aim of the present retrospective study was to evaluate the potential impact of 
microbiological analysis on the outcomes of periodontal therapy with and without the 
adjunctive use of systemic antibiotics in patients diagnosed with CP or AP. 
 
Materials and methods 
Data collection 
The present study had a retrospective design including previously collected health-related 
patient’s data were used. All available patient files were screened if 1) the patient`s 
agreement for the data use was provided, and 2) two microbiological tests (before and after 
non-surgical periodontal therapy (SRP)) were conducted. 
The sample size was the available data obtained during a three-year period (2012-2014). 
This time frame was chosen since during this period there were no changes in the routine 
microbiological methods used for the analysis of subgingival plaque samples.  
Inclusion criteria were the patient’s agreement to use health-related data for research 
purposes. The minimum age was 18 years. Furthermore, according to the data file patients 
presented with an untreated periodontitis (no supportive periodontal therapy and no 
periodontal treatment within one year), the clinical diagnosis of a CP or AP and 
microbiological analyses at baseline (before treatment and at 3-6 months after SRP). 
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Additionally, all microbiological results included the first line of bacteria (A. 
actinomycetemcomitans, P. gingivalis, T. forsythia, T. denticola, P. intermedia). Missing data 
were accepted for the other bacteria. In such situations, data were only included when they 
were available for both time-points.  
The clinical measurements were performed at six points using the same type of manual 
periodontal probe (UNC15; Hu-Friedy, Chicago, IL, USA). Microbiological samples were 
collected from the deepest sites at baseline without removing supragingival biofilm. Following 
collection, the samples were pooled. The treatment protocol included oral hygiene 
instructions followed by supra and subgingival SRP under local anesthesia. Post-treatment 
biofilm control was additionally optimized by using supragingival rinses with 0.1% 
chlorhexidine digluconate solution twice daily according to the standard protocol of our 
department. In patients with AP and severe cases of CP, mechanical debridement was 
followed by systemic administration of amoxicillin and metronidazole (each 500 mg three 
times per day) for a period of 7 days.  
Data from all vulnerable persons defined as age less than 18 years, pregnant women, 
prisoners, individuals unable to consent, were excluded. Additionally, patients receiving 
periodontal surgery between the two evaluation time points were excluded. 
If a patient’s file met the inclusion and exclusion criteria, the respective data were captured. 
This information included patient-related data (gender, age in years, systemic diseases 
(yes/no), and smoking habits), clinical data (diagnosis, number of teeth, number of sites with 
Probing Depths (PD) ≥5 mm, number of sites with Bleeding on Probing (BOP) as well as oral 
hygiene status expressed as plaque index according to O’Leary [21]. The results of the 
microbiological analysis were classified as follows for each bacterial species: 0 = no 
detection, 1 =  weak load, 2 = moderate load, and 3 = heavy load). 
The study protocol was submitted to and approved by the ethical commission of the Canton 
of Bern, Switzerland (Basec # 2016-00930). 
 
Data analysis 
Data processing calculated the per cent of reduction of sites with PD≥5 mm at T2 in 
comparison with T1. In addition, categorical data for bacterial species were dichotomized and 
the sum of positive results was calculated per patient for P. gingivalis, T. forsythia and T. 
denticola (and A. actinomycetemcomitans), respectively. 
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The primary outcome variable was the presence of P. gingivalis, T. forsythia and T. denticola 
(sum) at T1 in patients demonstrating a 90% reduction in the number of sites with PD ≥5 mm 
at T2 (90%-PD5). Secondary endpoints were the presence and categories of the other 
analyzed bacteria and with 50% reduction of numbers of sites with PD ≥5 mm at T2 (50%-
PD5). Additionally, the influence of the adjunctive use of antibiotics, the clinical diagnosis 
(e.g. AP or CP), the level of oral hygiene and of smoking habits on the clinical and 
microbiological outcomes were evaluated. 
Following descriptive statistics on all variables, a logistic regression analysis was performed 
to model the presence of 90%-PD5 against the sum of positive results of P. gingivalis, T. 
forsythia and T. denticola. Furthermore, the influence of the different variables was 
investigated with multiple regression analysis and general linear models for the analysis of 
variance and covariance. Secondary outcomes were compared between the groups. 
Statistical analysis was performed using the SAS POUZ LOGISTIC and GLM [22]. The level 
of significance was set to p=0.05.  
 
Results 
Study population and clinical variables 
A total of 102 patients (49 male, 53 female; mean age 46.1 years, range 19 – 81 years) 
fulfilled the inclusion criteria. The patients were diagnosed and treated by nine clinicians (8 – 
20 patients per clinician). Eighteen patients had been diagnosed with AP and 84 with CP, 
respectively. The clinical data including PD at sampling sites at T1 and T2 are summarized in 
Table 1. 
Microbiological outcomes 
Dichotomized data revealed differences between CP and AP at T1 with a higher prevalence 
of A. actinomycetemcomitans, E. nodatum and a lower prevalence of F. 
nucleatum/necrophorum in AP. Except for A. actinomycetemcomitans, F. nucleatum and 
Capnocytophaga sp. the presence of all other bacteria was reduced at T2 in comparison with 
T1 both in AP and CP patients, respectively. In patients with AP, A. actinomycetemcomitans 
was detected less frequently by tendency following non-surgical therapy. 
Analyzing if any of the bacterial species P. gingivalis, T. forsythia, T. denticola (and A. 
actinomycetemcomitans) was present in AP and CP patients revealed statistically significant 
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less positive results following non-surgical therapy in comparison to baseline. At T2, more 
positive results were found in CP than in AP patients (Table 2).  
 
Bacteria and response to treatment 
In patients with 90%-PD5, the presence of P. gingivalis, T. forsythia, T. denticola (sum) at T1 
did not present any statistically significant association (primary outcome variable). There was 
also no detectable association with 90%-PD5 when dichotomized data at T1 were employed. 
However, when using 50%-PD5, higher presence of T. denticola at T1 was associated with 
good response to therapy. Moreover, certain categories of bacterial counts (T. forsythia (3), 
T. denticola (2), C. rectus (2) as well as the combined presence of P. gingivalis, T. forsythia 
and T. denticola) were associated with good response to treatment (odds ratio (OR) between 
4.67 and 13.50). 
At T2, 90%-PD5 was statistically significantly associated with lower presence of T. forsythia 
and E. corrodens. In 50%-PD5, the presence of T. forsythia, T. denticola, C. rectus and the 
sum of positive results of P. gingivalis, T. forsythia and T. denticola together with certain 
single categories of analyzed bacteria, were negatively associated with the clinical outcomes 
(Table 2). 
Furthermore, we modeled the disease severity (defined by ≤20 sites with PD ≥5 mm, >20 
sites with PD ≥5) on 90%-PD5 and 50%-PD5. Any influence on treatment outcome by 
disease severity group was not seen (data not shown). 
 
Treatment outcome in association with the presence of bacteria, antibiotic treatment related 
to clinical diagnosis of periodontitis 
Seventeen out of the 18 AP patients received adjunctive antibiotics to non-surgical therapy 
antibiotics (AP-AB). The patient diagnosed with AP and treated without antibiotics was 
excluded from that analysis. Of the 84 CP patients, systemic antibiotics were administered to 
31 patients (CP-AB), whereas 53 patients were treated with non-surgical therapy alone (CP-
noAB).  
Using a general logistic model at T1, the clinical results revealed a difference between the 
subgroups. More specifically, the subgroup CP-AB presented with more sites with PD ≥5 mm 
than the subgroup CP-noAB. All clinical parameters were improved in all three subgroups 
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after non-surgical therapy. At T2 the PI revealed statistically significant differences. In both 
groups treated with adjunctive antibiotics (AP-AB, CP-AB), the plaque level was statistically 
significantly lower than in CP-noAB (Table 4). 
The sum of P. gingivalis, T. forsythia, T. denticola and A. actinomycetemcomitans decreased 
in each subgroup statistically significantly after non-surgical therapy. At T1 there was no 
difference between the subgroups, at T2 the value was higher in CP-noAB compared with 
AP-AB and CP-AB (Fig. 2). 
As the PI was different at T2 between the subgroups, logistic modeling included presence of 
bacteria at T1, antibiotic subgroup and PI at T2. The variable plaque score was dichotomized 
by using a cut-off of 20%. Logistic modeling to 90%-PD5 did not show any statistical 
significance. Using 50%-PD5 as a criterion, all models including first-line bacteria were 
statistically significant positive with p<0.01. In these models the impact (OR) of the adjunctive 
antibiotic group was between 2.70 and 52.4, the OR of PI was between 3.27 and 4.11 and 
the OR of bacteria at T1 ranged between 1.72 and 28.6 (any of P. gingivalis, T. forsythia, T. 
denticola; Table 5). 
 
Treatment outcome in association with presence of bacteria and smoking 
Among the patients included in the analysis 57 (56%) never smoked, from the 39 (38%) 
active smokers at T1 four patients stopped smoking during non-surgical periodontal therapy. 
Sixteen (61%) of the patients never smoked in the group demonstrating 90%-PD5, and 41 
(54%) in the group without 90%-PD5. There were no statistically significant differences in 
terms of bacterial presence at T1 and T2 between the smoking groups. When using GLM to 
model the impact of smoking, bacteria and antibiotics on 90%-PD5 and 50%-PD5 no 
statistically significant influence of smoking on response to treatment was found (p between 
0.233 and 0.560 for 90%-PD5 and between 0.342 and 0.940 for 50%-PD5).  
 
 
Discussion 
The present retrospective analysis has attempted to shed light on the clinically extremely 
important, but still controversially discussed, issue namely, the impact of microbiological 
diagnosis on the outcomes of periodontal treatment with or without adjunctive use of 
systemic antibiotics. The results appear to suggest that patients harboring before therapy P. 
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gingivalis, T. denticola and T. forsythia may benefit mostly from an adjunctive use of 
systemic antibiotics in conjunction with non-surgical therapy. Despite obvious limitations due 
to the retrospective nature of the study, the present data appear to indicate a potential 
benefit of performing microbiological diagnosis when considering the use of systemic 
antibiotics in conjunction with nonsurgical periodontal therapy. 
In our laboratory a nucleic-acid based strip-technology (micro-IDent®plus11 and 
microIDent®, Hain Lifescience, Nehren, Germany) is used for routinely sampled subgingival 
biofilm, procedure in laboratory is according to the manufacturer’s instruction. The test is able 
to identify 11 or five periodontopathogenic bacterial species. First, DNA is extracted by the 
Chelex method [23]. Thereafter, two (11 species) or one (five species) PCR runs are 
performed before subsequent reverse hybridization and analysis. In our laboratory the 
resulting bands for positive reactions are compared visually and categorized independently 
by two experienced persons. Sensitivity and specificity of the test kits was shown in several 
studies [13, 14]. Cut-off of the test confirmed for single species in laboratory is 103 for A. 
actinomycetemcomitans and 104 for the other species. Our own evaluation revealed an 
increase by about one log10 when several bacterial species to be detected in a sample are 
present. In most of the final analyses only dichotomized data of bacteria were included since 
no more differentiating results were obtained when using categories. The used cut-off of 104 
was tested to be clinical relevant for P. gingivalis [24]. Consequently, it may be sufficient and 
probably helpful also for the clinicians’ understanding to provide only qualitative results from 
laboratory when test system with cut-off is used. 
Meanwhile, new technologies allow the identification of species present in a complex 
microbiome. These investigations allow a better understanding of a complex ecosystem but 
are difficult to interpret by the clinician. Therefore, medical microbiology still focuses primarily 
on selected bacteria when analyzing an ecosystem (for example in cystic fibrosis, only 
certain bacterial species are used to identify the infection [25]). Despite the fact that the 
subgingival biofilm consists of about 1’000 species [26], only 11 species were assessed in 
that study. However, statistically significant results were mainly obtained for the three 
members of the so-called “red complex” underlining once more the importance of P. 
gingivalis, T. forsythia and T. denticola. These bacterial species are those most associated 
with periodontal disease [27]. 
According to the standard protocol used at the Department of Periodontology, University of 
Bern, the four deepest sites (preferably one per quadrant) are chosen. After air-drying and 
isolation by cotton rolls, each an endodontic paper point (ISO 50) is inserted into the selected 
site until resistance is felt for 20s. The supragingival biofilm is not removed before sampling. 
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The samples from the four different sites are pooled in the transport vials and immediately 
transferred to laboratory where they are stored at -20°C until analysis, which is regularly 
performed within one week. This approach is based on the findings which have shown that 
the microbiota is not very different in pockets with similar probing depths, irrespective of the 
region [28]. Detection frequency of periodontopathogens is higher when using pooled 
samples [17] and when supragingival plaque is not removed [29]. 
Comparing AP and CP, more positive results of A. actinomycetemcomitans and E. nodatum 
were found in AP patients. Regarding A. actinomycetemcomitans, this finding confirms those 
of a recent study where about 70% of positive samples were detected in patients diagnosed 
with localized AP [30]. In our study, half of the AP patients have been tested positively for A. 
actinomycetemcomitans. When interpreting these findings it has to be kept in mind that the 
clinical diagnosis of AP is often difficult [31]. Genotyping of A. actinomycetemcomitans for 
genotype b and c was not included in our statistical analysis due to the low numbers of 
samples being tested positively for that species. Genotype b was detected in 6 patients, 
whereas genotype c was found in 5 patients. Only once deletion within leukotoxin gene was 
present in a patient originating from North Africa. This is in line with the high prevalence of 
that clone in North Africa [32]. Other bacteria might contribute to a microbial dysbiosis 
triggering a rapid destruction of periodontal tissue. A recent study found A. 
actinomycetemcomitans in five of 19 biofilm samples of Sudanese AP patients whereas all 
samples of 15 periodontally healthy controls were negative [33]. Here, E. nodatum was also 
more prevalent in AP than in controls [33]  which may support a potential role of that species 
in AP. 
PD ≥5 mm represents a risk factor for further attachment and tooth loss [34]. Clinical 
outcome was defined as per cent of reduction of sites with PD ≥5 mm after non-surgical 
therapy. We did not detect an influence of the initial numbers of sites of PD ≥5 mm in our 
statistical evaluation. Two different levels were used to define high response to treatment, 
90% per cent and 50% of reduction of sites with PD ≥5 mm at T2 in comparison with T1.  In 
nearly all analyses (incl. the primary outcome presence of P. gingivalis, T. forsythia, T. 
denticola (sum) at T1), no influence of microbiological result on 90%-PD5 was observed. 
However, using 50%-PD5 revealed several interesting results. Presence of all P. gingivalis, 
T. forsythia and T. denticola and in particular of T. denticola at T1 und opposite, absence of 
any P. gingivalis, T. forsythia, T. denticola and in addition of C. rectus at T2 was associated 
with high response to therapy. The baseline findings of the present study are in line with 
those of a recent report, where higher proportions of Porphyromonas sp., Treponema sp. at 
baseline predicted a better treatment outcome [35]. Since the etiology of periodontitis is 
11 
 
linked with the prevalence of these bacterial species at high numbers, an effective 
elimination (below the detection level) improves obviously the clinical outcomes.  
Mechanical non-surgical therapy remains the gold standard in the treatment of periodontitis 
as it removes or destroys the subgingival biofilm [36]. Models confirmed the influence of 
selected bacteria (in particular of P. gingivalis, T. forsythia and T. denticola) on treatment 
outcome also when adjunctive antibiotics were applied. The protocol used in our Department 
considers the administration of amoxicillin and metronidazole only given in conjunction with 
non-surgical periodontal therapy. This combination has been repeatedly demonstrated to be 
beneficial for the treatment of AP [37]. Furthermore, recent systematic reviews have also 
demonstrated a profound effect of this combination upon clinical outcomes in CP patients 
[38]. In the present study, about half of the analyzed patients received adjunctive amoxicillin 
and metronidazole. However, it should be kept in mind that in the routine clinical setting, this 
number is probably lower since sampling for microbiological diagnostics is often linked with 
adjunctive antibiotic therapy. As shown in the baseline data, mean PD was higher in CP 
patients who received adjunctive antibiotics. However, the discussion about the role of 
adjunctive antibiotics in the treatment of CP is still controversial. While some authors 
recommend the routine use of adjunctive antibiotics [39, 40] others recommend a very 
restricted use [41]. On the other hand, the present findings are in line with those of a recent 
report on the changes in the subgingival microbiome up to one year post-treatment of 
patients treated with non-surgical periodontal therapy with or without amoxicillin and 
metronidazole pointing to the predictive value of specific subgingival bacterial profiles for the 
decision to prescribe antibiotics in the treatment of periodontitis [35].     
Our logistic analysis confirmed an impact of adjunctive antibiotics on the treatment response. 
However, antibiotics have side effects, e.g., 1-2% of individuals have allergy to penicillins 
[42], metronidazole was discussed having ototoxicity [43] and combined with penicillin it may 
cause nausea and diarrhea [44]. Moreover, the global problem of development of resistance 
associated with the consumption of antibiotics [45] demands a well indicated and very 
restricted use of these drugs [46]. E.g., World Health Organization is celebrating the “World 
Antibiotic Awareness Week” once per year, among others dentists are asked to handle 
antibiotics with care [47]. After non-surgical periodontal therapy, the PI was lower in the 
groups that received systemic antibiotics. Including this variable in logistic models underlines 
the impact of good oral hygiene on response to therapy. Since antibiotics do not destroy 
biofilms [48, 49], a potential psychological effect leading to improved oral hygiene measures, 
has also to be suggested in the patients receiving these highly potent drugs.    
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Limitations of the study are those of a retrospective study in general. Data were recorded as 
they appeared in the patient`s files and thus, potential bias in data recording cannot be 
completely excluded. Although guidelines for diagnostics and periodontal treatment exist, an 
influence by the individual clinician cannot be completely ruled out. The interval between the 
two time-points was in a range of 3 to 6 months. Moreover, non-recorded (e.g., due to not 
reporting by the patient) antibiotic intake for medical reasons might have also influenced the 
results. Furthermore, with a total number of 102 patients analyzed in this study, the final 
sample size was not very high. Consequently, potential differences between the groups may 
fail to reveal statistical significances.  
In summary, the present findings suggest that microbiological detection of the most important 
species associated with periodontal disease (P. gingivalis, T. forsythia, T. denticola, A. 
actinomycetemcomitans) appears to be sufficient to indicate microbial dysbiosis, and may 
help the clinician in the decision making process of using or not systemic antibiotics during 
non-surgical periodontal therapy.     
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Table 1  
Epidemiological and clinical data 
 
Variable T1: mean±SD T2: mean±SD  
Total (n) 102 102 
Gender: male/female 49/53  
Age: mean (range) 46.1 (19-81)  
Clinical diagnosis: AP/CP 18/84  
PD≥5 mm (n/patient) 39.61±26.27 12.78±13.77 
BoP (%) 48.39±22.72 19.67±14.36 
O’Leary (%) 48.53±24.34 22.02±15.84 
PD ( mean of the four 
sampling sites/patient) 
7.29±1.63 5.08±1.28 
Diff PD ≥5 mm (n)  26.82±22.52 
Diff PD ≥5 mm (%)  65.83±27.24 
Smoking: Non-smokers / 
smokers / former smokers (n) 
57/39/6 57/35/10 
90%-PD5 (n (%))*  26 (25.5) 
50%-PD5 (n (%))*  76 (74.5) 
 
*90% or 50% reduction in the number of sites with PD ≥5 mm at T2   
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Table 2 
Presence of selected bacterial species (qualitative data) at baseline (T1) and after non-
surgical therapy (T2) related to the clinical diagnosis of aggressive periodontitis (AP) 
and chronic periodontitis (CP) 
  
Bacterium AP (n=18) 
n (%) 
CP (n=84)  
n (%) 
P 
AP vs. CP 
A. actinomycetemcomitans 
T1 
T2 
P 
 
7 (38.9) 
2 (11.1) 
0.096 
 
11 (13.1) 
13 (15.5) 
0.593 
 
0.016* 
1.000 
P. gingivalis 
T1 
T2 
P 
 
14 (77.8) 
3 (16.7) 
<0.001** 
 
48 (57.1) 
25 (29.8) 
<0.001** 
 
0.119 
0.385 
T. forsythia 
T1 
T2 
P 
 
17 (94.4) 
4 (22.2) 
<0.001** 
 
77 (91.7) 
46 (54.8) 
<0.001** 
 
1.000 
0.018* 
T. denticola 
T1 
T2 
P 
 
16 (88.9) 
5 (27.8) 
<0.001** 
 
72 (85.7) 
36 (42.9) 
<0.001** 
 
1.000 
0.295 
 
P. intermedia  
T1 
T2 
P 
 
9 (50.0) 
2 (11.1) 
0.020* 
 
41 (48.8) 
15 (17.9) 
<0.001** 
 
1.000 
0.730 
P. micra 
T1 
T2 
P 
 
8 (53.3) 
2 (13.3) 
0.034* 
 
43 (67.2) 
21 (32.8) 
<0.001** 
 
0.374 
0.208 
F. nucleatum/necrophorum1 
T1 
T2 
P 
 
13 (86.7) 
10 (66.7) 
0.257 
 
64 (100.0) 
55 (85.9) 
0.003** 
 
0.034* 
0.126 
C. rectus 1 
T1 
T2 
P 
 
12 (80.0) 
5 (33.3) 
0.008** 
 
57 (89.1) 
27 (42.2) 
<0.001** 
 
0.391 
0.575 
E. nodatum1 
T1 
T2 
P 
 
9 (60.0) 
1 (6.7) 
0.005** 
 
17 (26.6) 
6 (9.4) 
0.005** 
 
0.029* 
1.000 
E. corrodens1 
T1 
T2 
P 
 
10 (66.7) 
4 (26.7) 
0.014* 
 
47 (73.4) 
33 (51.6) 
0.003** 
 
0.750 
0.094 
Capnoc. sp. 1 
T1 
T2 
P 
 
11 (73.3) 
9 (60.0) 
0.480 
 
34 (53.1) 
29 (45.3) 
0.336 
 
0.246 
0.393 
Pg, Tf, Td (any) 
T1 
T2 
P 
 
17 (94.4) 
5 (27.8) 
<0.001** 
 
81 (96.4) 
53 (61.9) 
<0.001** 
 
0.546 
0.010 
Pg, Tf, Td, Aa (any)    
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T1 
T2 
P 
17 (94.4) 
6 (33.3) 
<0.001** 
81 (96.4) 
54 (64.3) 
<0.001** 
0.546 
0.019 
 
1The second line species were analyzed at two time-points only in 15 patients with AP and 
64 patients with CP. 
Intra-group differences were determined by using Mc Nemar’s test, inter-group differences by 
using Fisher exact test.   
* significant difference p<0.05 
** significant difference p<0.01 
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Table 3 
Association of presence of bacteria at T1 and T2 as well as of categories (3 heavy load, 2 moderate load, 1 weak load, 0 no detection; for single 
categories only significant results vs. 0 are mentioned) with success of therapy (90% and 50% of reduction of sites with PD ≥5mm)  
Bacteria Time-
point 
90% of reduction of sites with PD ≥5mm 
       0;1                                 categories 
P; OR [CI]          all  (P)     vs. 0 Load: P; OR [CI]                 
50% of reduction of sites with PD ≥5mm 
        0;1                                 categories 
P; OR [CI]          all  (P)     vs. 0 Load: P; OR [CI]    
     
A. actin.         
 
T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  n.s. n.s.  
P. gingivalis   
  
T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  n.s. n.s.  
T. forsythia T1 n.s. n.s.  n.s. n.s. 3: 0.039; 6.25 
[1.10;35.68] 
T2 0.019; 0.31 
[0.12; 0.82] 
n.s. 2: 0.039; 0.28 
[0.09;0.92] 
<0.001; 0.15 
[0.05;0.43] 
0.004 1: 0.001; 0.09 
[0.02;0.38] 
2: 0.003; 0.17 
[0.05;0.54] 
T. denticola T1 n.s. n.s.  0.030; 3.63     
[1.13; 11.63] 
n.s. 2: 0.013; 4.67 
[1.38;15.79] 
T2 n.s. n.s. 2: 0.048; 0.27 
[0.07;0.99] 
0.000; 0.24     
[0.09; 0.63] 
0.012 2: 0.013; 0.27 
[0.10;0.76] 
P. intermedia T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  n.s. n.s.  
P. micra T1 n.s. n.s.  n.s. n.s.  
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T2 n.s. n.s.  n.s. n.s.  
F. nucl./necr. T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  n.s. n.s.  
C. rectus T1 n.s. n.s.  n.s. n.s. 2: 0.027; 8.67 
[1.28;58.85] 
T2 n.s. n.s.  0.007; 0.18     
[0.05; 0.63] 
0.030 1: 0.026; 0.16 
[0.03;0.81] 
2: 0.006; 0.11 
[0.02;0.54] 
E. nodatum T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  n.s. n.s.  
E. corrodens T1 n.s. n.s.  n.s. n.s.  
T2 0.028; 0.28     
[0.09; 0.87] 
n.s.  n.s. n.s.  
Capnoc. sp. T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  n.s. n.s.  
P. g., T.f., T.d.1 T1 n.s. n.s.  n.s. n.s. 3: 0.031; 13.50 
[1.27;143.64]                
T2 n.s. n.s.  0.002; 0.155     
[0.05; 0.49] 
<0.001 2: <0.001; 0.07 
[0.02;0.26] 
3:  0.039;  0.23 
[0.06;0.93] 
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A. a., P. g., T.f., 
T.d.1 
T1 n.s. n.s.  n.s. n.s.  
T2 n.s. n.s.  0.004; 0.18     
[0.06; 0.58] 
0.008 2: 0.003; 0.03 
[0.02;0.50] 
3: 0.001; 0.11 
[0.03;0.42] 
1presence (0;1): any; categories: sum of presence  
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Table 4 
Clinical variables related to clinical diagnosis of aggressive periodontitis (AP) and chronic periodontitis (CP) and with adjunctive 
antibiotic treatment (AB) and without antibiotic (noAB) at baseline (T1) and after non-surgical therapy (T2)   
 AP-AB (n=17) 
 
T1              T2 
CP-AB (n=31) 
 
T1              T2 
CP-noAB (n=53) 
 
T1              T2 
P (GLM) 
 
T1              T2 
P single statistically 
significant results 
T1                       T2 
PD≥5 mm (n: mean ± SD) 
 
       P (Student) T2 vs. T1 
43.6±32.7 10.2±11.2 48.7±29.7 11.8±13.4 32.7±19.9 13.6±14.4 0.019 0.635 CP-AB vs. CP-
NoAB: 0.007 
 
 <0.001  <0.001  <0.001     
BOP (%: mean ± SD) 
      P (Student) T2 vs. T1 
48.0±24.1 17.7±16.5 48.5±23.3 16.9±16.1 48.0±22.4 21.4±11.9 0.995 0.321   
 <0.001  <0.001  <0.001     
O’Leary (%: mean ± SD) 
  
 
      
      P  (Student) T2 vs. T1 
40.7±28.0 14.3±9.02 44.5±24.0 16.5±11.1 52.6±22.2 27.4±11.8 0.125 <0.001  AP-AB vs. CP-
noAB: 0.002 
CP-AB vs. CP-
NoAB: 0.002 
 <0.001  <0.001  <0.001     
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Table 5 
Logistic modelling of presence of bacteria at T1, O’Leary plaque score <20% at T2 and antibiotic group (aggressive periodontitis with adjunctive 
antibiotics (AP-AB), chronic periodontitis with adjunctive antibiotic treatment (CP-AB) and without antibiotic (CP-noAB) 
Species 90%-PD5 
P  
50%-PD5 
P 
OR of statistically significant results 50%PD5 
   bacteria 1;0 at T1         O’Leary 0;1 at T2        AP-AB vs. CP-noAB    CP-AB vs. CP-noAB 
A. actin. n.s. 0.003 3.29 [0.57; 18.8] 4.11 [1.36; 12.5] 2.70 [0.50; 14.6] 14.9 [1.83; 122] 
P. gingivalis   n.s. 0.003 2.02 [0.70; 5.89] 3.27 [1.10; 9.72] 3.25 [0.63; 16.8] 18.5 [2.23; 153] 
T. forsythia n.s. 0.008 15.9 [1.31; 192] 3.48 [1.13; 10.8] 4.40 [0.78; 25.0] 52.4 [2.96; 926] 
T. denticola n.s. 0.002 4.93 [1.16; 21.0] 3.39 [1.12; 10.3] 4.15 [0.75; 23.0] 20.3 [2.29; 179] 
P. intermedia n.s. 0.004 1.72 [0.60; 4.95] 3.60 [1.21; 10.6] 3.76 [0.73; 19.3] 18.0 [2.18; 149] 
P. micra n.s. n.s.     
F. nucl./necr. n.s. 0.047 8.12 [0.23; 288] 3.30 [0.90; 12.2] 3.25 [0.35; 30.1] 8.04 [0.93; 69.5] 
C. rectus n.s. 0.036 5.58 [1.01; 29.5] 4.57 [1.14; 18.3] 2.41 [0.37; 15.6] 8.49 [0.91; 79.3] 
E. nodatum n.s. n.s.     
E. corrodens n.s. n.s.     
Capnoc. sp. n.s. n.s.     
P. g., T.f., T.d. n.s. 0.004 28.6 [1.72; 477] 3.82 [1.23; 11.9] 4.87 [0.80; 29.6] 28.4 [2.18; 369] 
A. a., P. g., T.f., T.d. n.s. 0.004 28.6 [1.72; 477] 3.82 [1.23; 11.9] 4.87 [0.80; 29.6] 28.4 [2.18; 369] 
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Fig. 1 
Flow chart of the data assessment and analyses 
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Fig. 2 
Sum of positive results / sample of Aggregatibacter actinomycetemcomitans, Porphyromonas 
gingivalis, Tannerella forsythia and Treponema denticola (mean and SD) in subgingival 
plaque obtained in aggressive periodontitis with adjunctive antibiotics (AP-AB), chronic 
periodontitis with adjunctive antibiotics (CP-AB) and chronic periodontitis without adjunctive 
antibiotics (CP-noAB) at baseline (T1) and after non-surgical therapy 
(Wilcoxon two-sample and Wilcoxon matched-pairs tests) 
 
